Navigation Links
Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
Date:3/23/2011

VANCOUVER, British Columbia, March 23, 2011 /PRNewswire/ -- Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

The Wightman Award is another major honour for Dr. Hayden, having previously been awarded the Order of Canada and Order of British Columbia, the Canadian Institutes of Health Research's Health Researcher of the Year Award, LifeSciences BC's Genome BC Award for Scientific Excellence and the Prix Galien Canada.

"I am thrilled to receive this award," said Dr. Hayden during the awards ceremony this morning in Toronto.  "As a physician scientist, to whom chance has given unusual opportunities, I am deeply aware of the degree to which my own success today is built upon the work, cooperation and struggles of others."

"This is a wonderful moment for Michael and the Xenon team is extremely proud of Michael's profound achievements.  His scientific and entrepreneurial talents and the commitment he has made to finding novel cures for difficult to treat diseases have made us a better company and Canada a better scientific community," said Dr. Simon Pimstone, a co-founder and President and Chief Executive Officer at Xenon Pharmaceuticals Inc. in Vancouver, Canada.

The Gairdner Awards are a highly respected international prize.  Ten of the last 24 Nobel Prizes in medicine or physiology have been awarded to past Gairdner recipients.  Prior to Dr. Hayden winning the Wightman Award, the last British Columbian to receive a Gairdner Award was the late UBC Chemistry Prof. Michael Smith, who won the 1986 Gairdner Foundation International Award and went on to win the 1993 Nobel Prize for Chemistry.

"I have known Michael and seen him in action for approximately twenty years and can think of no one in Canada more deserving," said Mr. Michael Tarnow, the Chairman of Xenon's Board of Directors and a past President and CEO of Merck Frosst Canada.  "Michael's research is innovative, meaningful and far reaching and is touching lives and providing hope for patients and family members literally all over the world.  Michael is a most deserving recipient."

An author of more than 600 publications, Dr. Hayden is the most cited author on Huntington's disease in the world.  He is well known for having developed a predictive genetic test for Huntington's disease, which was the first ever predictive test for any genetic disorder.  With Xenon he has also identified genes associated with rare disorders such as Tangier disease, juvenile hemochromatosis and congenital insensitivity to pain.  These discoveries are leading to novel approaches for treating common diseases such as cardiovascular disease, anemia and pain.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact.  These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements.  Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenon Announces Appointment of EVP, Research & Development
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. Xytis Names Gordon H. Busenbark as Chief Financial Officer
5. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
6. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
11. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):